Initiator Pharma Gets UK CTA Approval For Phase 2a Study

RefinitivMeno di 1 minuto di lettura

Initiator Pharma A/S INIT:

RECEIVES UK CTA APPROVAL TO INITIATE PHASE 2A STUDY IN VULVODYNIA
FIRST PATIENTS EXPECTED TO BE ENROLLED IN Q4 2025

© Copyright Thomson Reuters 2025. Click For Restrictions - https://agency.reuters.com/en/copyright.html

Accedi o crea un account gratuito per leggere queste notizie